NEW YORK, August 28, 2017 /PRNewswire/ --
A research report by Life Science Intelligence (LSI), Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year 2030. Although most cases are not reported, it is estimated that more than 30 million men affected in the United States. The report indicates that ED is more common in men older than age 65, most men older than the age of 40 experience occasional difficulty and it is estimated that more than 50% of men older than the age of 40 report periodic episodes of ED. Creative Medical Technology Holdings, Inc. (OTC: CELZ), Easton Pharmaceuticals, Inc. (OTC: EAPH), VIVUS, Inc. (NASDAQ: VVUS), Apricus Biosciences, Inc. (NASDAQ: APRI), ViaDerma, Inc. (OTC: VDRM),
A new report by Visiongain forecasts that the world market for sexual dysfunction drugs will reach $7.7 billion in 2019, or rising further to 2026. The market will be stimulated by ageing populations, rising incidence of cardiovascular and metabolic disorders, new drug delivery technologies, emerging test techniques and the rising female sexual dysfunction drugs submarket. Sandra Wenas, a senior pharmaceutical industry analyst in Visiongain stated, "We believe that there will be positive changes in the way societies perceive male and female sexual dysfunctions. Increased awareness and more self reporting will expand the size of patient populations. Presently there is still divided opinion on whether female sexual dysfunction is a physiological disease that needs medication or whether it is a psychological condition."
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) earlier today announced that, "completion of enrollment in the Company's clinical trial assessing safety and efficacy of its CaverstemTM procedure to treat erectile dysfunction in patients who do not respond to currently available treatments. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
"The CaverstemTM procedure, which uses the patient's own bone marrow derived stem cells to induce arterial and venous regeneration, is an outpatient procedure able to be conducted by Urologists in their medical facilities. We are using a patient's own cells and we do not manipulate the stem cells through the use of chemicals, growth factors or expansion and have experienced no procedure-related safety issues," said Dr. Thomas Ichim Co-Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.
The clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial is sponsored by us based on our patented technology and is conducted by Dr. Jacob Rajfer, Principal Investigator and Los Angeles Biomedical Institute at Harbor - UCLA Hospital in Torrance, CA.
"I am pleased with the expedience and efficiency at which enrollment was reached. As someone who regularly sees patients suffering from treatment non-responsive erectile dysfunction, I am excited to see the development of a novel approach to treating this condition using the patient's own natural regenerative processes," said Dr. Alexander Gershman, member of the Company's Scientific Advisory Board and Director of Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center."
"We are very fortunate to work with the expert team at Los Angeles Biomedical Institute - UCLA/Harbor Hospital who have done an outstanding job with subject recruitment, screening, treatment and follow-up. We firmly believe that we are on schedule for commercialization of the Caverstem TM procedure through publication and presentation of trial results, marketing, licensing, training and sales in 2018," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.
Easton Pharmaceuticals, Inc. (OTC: EAPH) s is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. According to the company's Product and Market Overview, "When it comes to treating pain, sexual dysfunction and other disease states that emanate from structures of the body below the skin, topical therapy is not effective unless the therapeutic agent can cross the outer layer of the skin (stratum corneum) which acts as a protective barrier. This layer consists of numerous dead cells and cells in transition, which collectively forms an effective barrier to penetration of substances, such as bacteria, in the air or in water. Thus the stratum comeum plays an important role in protecting the body from invasion by harmful substances."
VIVUS, Inc. (NASDAQ: VVUS) is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. STENDRA or avanafil is approved in the U.S. by the FDA for the treatment of erectile dysfunction. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. On August 3rd, the company reported financial results for the quarter ended June 30, 2017.
Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has a product called Vitaros, a candidate in the United States for the treatment of erectile dysfunction. Vitaros is a topically-applied cream formulation of alprostadil, which dilates blood vessels, combined with a proprietary permeation enhancer NexACT, which directly increases blood flow to the penis, causing an erection. Vitaros is currently in development in the U.S. and approved and commercialized in certain countries outside of the U.S. Allergan owns the rights to Vitaros in the U.S. and in September 2015, the company entered into an agreement with Allergan to license the U.S. development and commercialization rights for Vitaros.
ViaDerma, Inc. (OTC: VDRM) is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. The company's lead product candidate, Vitastem, broad spectrum tetracycline-based topical antibiotic with proven results. Vitastem could be used in a variety of potential markets, including erectile dysfunction, burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, and pain management.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: [email protected] , +1-877-601-1879